基尼尔尼古丁胺胺在耐药性急性髓性白血病中表现出抗白血病活性
Baskar Ramdas1, Neetu Dayal2, Ruchi Pandey1
1Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
The Journal of clinical investigation
|July 1, 2024
概括
基于尼古丁胺的新型FLT3抑制剂HSN608和HSN748对FLT3突变的急性髓性白血病 (AML) 显示出强大的疗效. 这些化合物对抗耐药突变有效,并在体内表现优于吉尔特里尼布.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 激活FLT3突变导致急性髓性白血病 (AML) 和患者的生存率低下.
- 对当前FLT3抑制剂的耐药性源于二次突变和替代生存途径.
研究的目的:
- 确定针对AML中的FLT3突变的新型治疗剂.
- 评估基于尼古丁胺的新型抑制剂对耐药FLT3突变的疗效.
主要方法:
- 基于尼古丁胺的新型FLT3抑制剂 (HSN608和HSN748) 的鉴定和表征.
- 对FLT3突变的抑制活性评估,包括耐药变异.
- 在AML的临床前模型中评估抗白血病活性,包括复发/耐药和TET2突变的AML.
- 在体内比较HSN748与FDA批准的FLT3抑制剂吉尔特里尼布.
主要成果:
- 在亚纳米度下,HSN608和HSN748针对FLT3突变.
- 这些化合物对耐药的二次FLT3突变表现出强烈的活性.
- 与吉尔特利尼布相比,HSN748在体内表现出对FLT3-ITD的优越抑制活性.
- 在耐药性,复发性/耐药性和TET2突变型AML模型中观察到抗白血病效应.
结论:
- 基于尼古丁胺的新型FLT3抑制剂HSN608和HSN748是AML的有希望的治疗候选者.
- 这些药物对FLT3突变是有效的,包括那些对现有疗法的耐药性.
- HSN748显示出作为FLT3突变AML的优质治疗选择的潜力.
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


